JAK2 and lymphoma: JAK2 mutations were not detected; TP53 gene mutations were restricted to three lymphoma patients with a median VAF 11%; range 10–52% (p = 0.0074); ASXL1 gene mutations were restricted to two AML patients (Table S2).